Estrella Immunopharma Inc.
ESLA evidence brief
What we can confirm
- BioSniper Score:
- 3.8 / 10
- Market Cap:
- $28.7M
- Lead Asset:
- eb103 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for ESLA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ESLA
Estrella Immunopharma Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors, currently conducting a Phase I/II clinical trial for its lead candidate EB103.
Key risk: Cash runway risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Estrella Immunopharma Inc..
Estrella Immunopharma Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors, currently conducting a Phase I/II clinical trial for its lead candidate EB103.
- Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors [sec_mda · as of 2026-08-13].
- Lead product candidates are EB103 and EB104, with EB103 targeting CD19 using ARTEMIS® T cell technology licensed from Eureka Therapeutics [sec_mda · as of 2025-08-12].
- The FDA cleared the IND for EB103 on March 2, 2023, allowing the Phase I/II STARLIGHT-1 clinical trial to proceed [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported cash & equivalents of $0.1M, net income of -$2.3M, and shareholders' equity of -$7.4M [latest reported financials].
- As of June 30, 2026, the accumulated deficit was approximately $41.6 million [sec_mda · as of 2026-08-13].
What works
- The FDA has cleared the IND for EB103, enabling the company to conduct its Phase I/II STARLIGHT-1 clinical trial [sec_mda · as of 2026-08-13].
- The company has dosed patients in its clinical trial, with nine patients dosed as of September 30, 2025, and a second clinical trial site activated [sec · filed 2026-01-16].
- Estrella has secured a licensing agreement with Eureka Therapeutics for ARTEMIS® T cell technology, a potentially differentiated platform [sec_mda · as of 2025-08-12].
What to weigh
- The company has a very low cash position of $0.1M as of June 30, 2026, and negative shareholders' equity of -$7.4M [latest reported financials].
- Management has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and need for additional financing [sec_mda · as of 2026-08-13].
- The company reported a net loss of approximately $4.6 million and net cash used in operating activities of approximately $8.5 million as of June 30, 2026 [sec_mda · as of 2026-08-13].
- The company has an accumulated deficit of approximately $41.6 million as of June 30, 2026 [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Estrella is a clinical-stage biopharmaceutical company developing T-cell therapies.
“Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies with the capacity to potentially cure patients with blood cancers and solid tumors.”
SEC MD&A · August 13, 2026
FDA cleared IND for EB103 on March 2, 2023.
“On March 2, 2023, the FDA cleared the IND application for EB103, allowing Estrella to proceed with the Phase I/II STARLIGHT-1 Clinical Trial.”
SEC MD&A · August 13, 2026
Management expresses substantial doubt about going concern.
“Our recurring losses from operations, accumulated deficit, and need for additional financing to fund future operations, raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2024-06-01 · Phase2_Start: An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL) — This marks the start of Phase II portion of the STARLIGHT-1 trial, a key milestone for advancing EB103.
Risks & what to watch (3)›
Key risks
- Cash runway risk — Cash & equivalents of only $0.1M as of 2026-06-30, with negative equity, indicating very limited liquidity [latest reported financials].
- Going concern uncertainty — Management states that recurring losses and accumulated deficit raise substantial doubt about ability to continue as a going concern [sec_mda · as of 2026-08-13].
- Clinical trial execution risk — The Phase I/II STARLIGHT-1 trial is early-stage (9 patients dosed as of Sep 2025) and requires significant additional funding to complete [sec · filed 2026-01-16].
What to watch
- Ability to raise additional financing to fund ongoing operations and clinical trial [sec_mda · as of 2026-08-13].
- Progress and enrollment updates for the STARLIGHT-1 Phase I/II clinical trial of EB103 [sec · filed 2026-01-16].
- Any updates on the development of EB104, the second lead product candidate [sec_mda · as of 2026-08-13].
- Financial reports for subsequent quarters to monitor cash position and accumulated deficit trends [latest reported financials].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run Estrella Immunopharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Estrella Immunopharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$2M
Lead: Phase 1/Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$5.5M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 4,099,000 | $4.3M |
| vanguard capital management llc | 382,469 | $405K |
| wells fargo & company/mn | 264,388 | $280K |
| geode capital management, llc | 157,485 | $167K |
| vanguard fiduciary trust co | 64,921 | $69K |
| renaissance technologies llc | 62,795 | $67K |
| state street corp | 43,252 | $46K |
| blackrock, inc. | 39,890 | $42K |
| northern trust corp | 19,624 | $21K |
| us bancorp \de\ | 16,904 | $18K |
Showing top 10 of 16 institutional holders of Estrella Immunopharma Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 3.8%
- Days to cover
- 11.8
- Shares short
- 626,324
- Daily short volume (Oct 12, 2026)
- 55.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ESLA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Estrella Immunopharma Inc.?
Estrella Immunopharma Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors, currently conducting a Phase I/II clinical trial for its lead candidate EB103.
What is Estrella Immunopharma Inc.'s lead drug candidate?
Estrella Immunopharma Inc.'s most advanced tracked candidate is eb103 (Phase 1/Phase 2) for B-Cell Non-Hodgkin's Lymphoma (NHL).
Who is the CEO of Estrella Immunopharma Inc.?
Dr. Cheng Liu Ph.D. is the chief executive officer of Estrella Immunopharma Inc. (ESLA).
Where is Estrella Immunopharma Inc. headquartered?
Estrella Immunopharma Inc. (ESLA) is headquartered in EmeryVille, CA, United States.
What therapeutic areas does Estrella Immunopharma Inc. focus on?
Estrella Immunopharma Inc. develops therapies across Oncology, Gene Therapy, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.